Routine screening for ovarian cancer a failure: study

Routine screening for ovarian cancer is ineffective and at times can do more harm than good, a panel of cancer specialists has concluded.

"There is no existing method of screening for ovarian cancer that is effective in reducing deaths," said US Preventive Services Task Force member and chair Dr Virginia Moyer.

"In fact, a high percentage of women who undergo screening experience false-positive test results and consequently may be subjected to unnecessary harms, such as major surgery," added Moyer in a statement on the group's website and in the .

The tests include ovarian scans and blood tests that look at a marker that can be linked to the disease.

The group said they are not recommended routinely for women who do not show signs of the disease, or who have (BRCA1 and BRCA2) that put them at a greater risk of developing it.

Other medical groups already have made similar recommendations including the "" and "American Congress of Obstetricians and Gynecologists."

is fairly rare with 22,200 new cases a year in the United States and 15,500 deaths.

add to favorites email to friend print save as pdf

Related Stories

U.S. panel rejects ovarian cancer screening

Apr 10, 2012

(HealthDay) -- A leading U.S. government panel has renewed its 2004 recommendation that women at average risk for ovarian cancer not get screened for the disease.

Recommended for you

How a common antacid could lead to cheaper anti-cancer drugs

28 minutes ago

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

Vaccines may make war on cancer personal

39 minutes ago

In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at Washington University ...

Funding to investigate an alternative to chemotherapy

1 hour ago

Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer ...

Enzyme may be key to cancer progression in many tumors

1 hour ago

Mutations in the KRAS gene have long been known to cause cancer, and about one third of solid tumors have KRAS mutations or mutations in the KRAS pathway. KRAS promotes cancer formation not only by driving ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.